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Histopathology, the examination of an architecturally artefactual, two-
dimensional and static image remains a potent tool allowing diagnosis and
empirical expectation of prognosis. Considerable optimism exists that the
advent of molecular genetic testing and other biomarker strategies will
improve or even replace this ancient technology. A number of biomarkers
already add considerable value for prediction of whether a treatment will
work. In this short review we argue that a systems medicine approach to
pathology will not seek to replace traditional pathology, but rather aug-
ment it. Systems approaches need to incorporate quantitative morphologi-
cal, protein, mRNA and DNA data. A significant challenge for clinical
implementation of systems pathology is how to optimize information avail-
able from tissue, which is frequently sub-optimal in quality and amount,
and yet generate useful predictive models that work. The transition of histo-
pathology to systems pathophysiology and the use of multiscale data sets
usher in a new era in diagnosis, prognosis and prediction based on the
analysis of human tissue.
Introduction
Modern pathology is currently cresting a new techno-
logical wave driven by the generation of complex ‘big
data’ through the adoption of novel -omics and digital
disciplines. There is a question, however, of how to
retrieve optimal useful information from these large
data sets in an efficient and clinically relevant manner.
The information harvested from the new technologies
aligns itself perfectly for the adoption of a systems
medicine approach. Although there are differing
schools of thought as to how to define systems medi-
cine, in this review we refer to systems medicine as
suggested by CASyM: ‘Systems Medicine involves the
implementation of Systems Biology approaches in
medical concepts, research and practice, through itera-
tive and reciprocal feedback between data-driven
computational and mathematical models as well as
model-driven translational and clinical investigations’
(https://www.casym.eu/what-is-systems-medicine). Sys-
tems medicine is therefore where specific but large and
static data sets acquired across multiple modalities are
used to construct computational models for the
dynamic prediction of disease progression or response
to treatment at a personal level. Systems medicine
must be an approach which can be implemented in the
clinic and directly benefit patient treatment decisions
and outcome. Classical histopathology, however, has
in some ways always tried to practice systems medi-
cine. Histopathology, where a pathologist microscopi-
cally directly observes the complex diseased tissue
system and its interaction with the host microenviron-
ment, and attempts to mentally compute these multiple
signals into a prognosis, has long been the gold
standard in the clinic. The diagnosis from histopathol-
ogy has been a model, albeit empirical, seeking to
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derive dynamic meaning of what has happened and
what is likely to happen from a static two-dimensional
image where secondary information is presented in the
artefact that is a tissue section (Fig. 1). From this pre-
mise a number of robust, clinically validated tools
have evolved with evidence showing that the most sim-
ple (e.g. Dukes’ staging of colorectal cancer) outlive
more complex variants [1]. Standardization of data,
and how data are acquired, has long been a goal with
internationally agreed criteria for staging cancers such
as the TNM classification (tumour size, lymph node
status, metastasis) facilitating data transfer between
centres and greatly augmenting the possibility of con-
ducting multicentre clinical trials [2]. The advent of the
minimal data set brings a deterministic approach to
how biopsy tissue samples are reported, and arguably
in some situations points the way for non-medical
pathologists to do much of the reporting which still
remains largely the province of medically trained
senior pathologists. In essence this approach is empiri-
cal, pragmatic and practical because it allows for the
variation that inevitably occurs during tissue accrual
and processing, the whole emphasis being what infor-
mation can be passed back to the clinician. Thus clas-
sical histopathology is adept at dealing with
imperfection, poor sample, small size of biopsy and
poor tissue orientation because the pathologist can
easily observe and disregard these artefacts and preen
the pertinent information from the stained heteroge-
neous tissue section. The objective is to frame the tis-
sue along with what it reveals in a useful model which
prompts particular actions by the referring clinician.
However, to train a pathologist may take 5 or more
years and is expensive both in training and in mainte-
nance, and the requirement for ever more specializa-
tion means that few pathologists now retain a broad
perspective on all disease. Instead pathologists are
increasingly encouraged to become super-knowledge-
able in narrow areas. This brings huge benefits and
allows even more accuracy and consistency between
centres, but tends to focus more on diagnosis rather
than the historical mix of diagnosis plus prediction of
what is likely to happen. There are geographical varia-
tions in pathology with nomenclature differences
between Europe and the USA and different prevalence
of some diseases, e.g. in the Far East compared with
Europe. But pathologists are a well-connected network
and these differences are used constructively to eluci-
date underlying mechanisms of disease. Similarly, there
is growing awareness that animal disease and compar-
ative pathology offer new insights into human patho-
physiology [3]. Thus histopathology, as quintessentially
a morphological discipline, is entering a new phase
with the potential to address phenotype in a clinically
useful way whilst also pointing to underlying mecha-
nisms.
Despite the success and evolution of standardized
pathology, or perhaps because of it, pathology to some
extent has been a bystander for much of the advent of
-omics and digital technologies, although it is now
joining the movements. Although pharmacogenomics
has been around for some time it has had little effect
on pathology whereas an explosion in biomarker
research is making a definite mark [4]. The current
mantra is that a biomarker should accompany a new
therapy, suggesting that intrinsically we accept that
empiricism is less than adequate for the prescription of
new drugs which may be very costly and carry signifi-
cant side effects. This is an important development
and recognizes that histopathology has been very good
at making diagnoses, particularly since the advent of
routine immunohistochemistry, to elucidate the puta-
tive histogenesis of tumour cells and therefore catego-
rize cancer origin and subtype more accurately. This
review is not the place to critique whether histogenesis
is a meaningful concept in tumour biology, but suffice
it to say that increasing knowledge about stem cell-
ness, reprogramming and stem cell niches and their
response to treatment, challenges the simplistic
assumptions underlying much diagnostic immunohisto-
chemistry-based taxonomy [5]. Standardization of
diagnostic labelling and collection of clinical informa-
tion, in all its forms, means that, in many disease set-
tings, pathology is now also very good at informing
prognosis. This is a useful adjunct to planning patient
Fig. 1. Standard histological preparation of a colon cancer sample.
Irregular glands, necrosis and invasion into the collagenous stroma,
combined with a macroscopic assessment of degree of spread,
give valuable and accurate prognostic data for categories of
patients, but very little personalized information.
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management but falls some way short of the ideals of
4P medicine, particularly in the areas of predictive,
personalized and participatory medicine [6] where a
systems medicine approach could prove beneficial.
Some immunohistochemical markers such as oestrogen
receptor status, in combination with specifically tar-
geted drugs such as oestrogen antagonists, have
brought prediction nearer reality; however, the predic-
tive value for an individual is considerably less valu-
able, in pharmaceutical terms, than the predictive
value for a group [7]. But the challenge and promise is
clear: pathology can and should inform not just diag-
nosis and prognosis, but also prediction of what the
outcome is going to be after a particular course of
treatment. The routine measurement, although we use
the term guardedly because it is at best a semi-quanti-
tative ranking algorithm, of oestrogen receptor evolved
from more intricate studies of receptor biochemistry
[8]. These required fresh tissue, and minimal amounts
of cancer versus non-cancerous tissue in the sample,
and although the output was a precise estimation the
results were grouped to decide treatment. In other
words, there were many logistical problems conducting
the original biochemical assay which were circum-
vented by accepting a more robust but much less
quantitative assay. This is the crux of understanding
the value of histopathology in systems medicine: it is
not a question of greater accuracy or precision alone,
nor is it the methods to collect tissue in a pristine
state, although that is a great goal; rather it is the abil-
ity to take whatever information that can be distilled
from tissue and use it in a way that wastes nothing,
covers doubt and uncertainty and informs clinical
management [9]. Pathology is and should be robust in
a modelling sense. More recently it has become appar-
ent that the integration of histopathology with other
streams of data can significantly add value to, and also
challenge and help form, strategies which seek to draw
together disparate strands to lead to a diagnosis,
inform prognosis and increasingly allow prediction of
likely response to therapy. Pathologists already utilize
the molecular and morphological heterogeneity in can-
cer to stratify patients into subgroups with differing
prognostic or predictive outcomes. This new pathologi-
cal knowledge of the difference in a patient’s cancer
and treatment strategy bears a higher success rate in
treating patients and their overall quality of life than a
‘one treatment fits all’. This is eloquently exemplified
in the treatment of colorectal cancer over the last dec-
ade. Previous to targeted biological treatment
advanced colorectal patients were treated with FOL-
FOX or FOLFIRI. Targeted therapy against epider-
mal growth factor receptor (EGFR) through
administration of cetuximab has shown promising
results with increased progression-free survival com-
pared with chemotherapy [10]. EGFR inhibition, how-
ever, only shows positive results to patients with wild-
type KRAS [11,12], and those patients with mutations
downstream of EGFR such as KRAS, BRAF [13,14]
and PIK3CA [15] show poor response to targeted
EGFR monoclonal antibodies such as cetuximab or
panitumumab. In fact it has been shown that mono-
clonal antibody inhibition of EGFR in combination
with FOLFOX may actually have detrimental effects
on patients with mutant KRAS colorectal cancer [16].
The explosion of data that are being produced and
published from proteomic, genomic, transcriptomic
and morphometric studies has added value to histopa-
thology. The sheer volume of information, however,
may be difficult to handle and real clinical impact may
only occur once complex multiple biomarker signa-
tures are combined into a predictive model. It is within
these situations that a systems medicine approach may
allow multimodality computation of complex data sets
and bring clarity to the pathologist and oncologist.
There are some key principles learned from pathology
that may help facilitate discussion on wider aspects of
the application of systems biology approaches in medi-
cine.
The problem of imperfection
Data sets and samples derived from patients are often
small or incomplete. The understandable response in
seeking to apply systems medicine type approaches is
to ensure that more data are collected in a standard-
ized fashion, larger tissue samples are obtained and
handled in appropriate ways, and appropriate resource
is allocated to the task. As with all automated and
computational analysis the quality of the end result is
intrinsically linked to the quality of the data input into
the model and systems medicine is no different. It
makes complete sense to have better data, consistent
high quality biological resources and standardization;
poor quality data will only result in poor quality out-
puts. However, the problem with this approach is that
ultimately it will fail because some clinical problems
are probably not soluble by these means. For example,
to investigate signalling pathways it is essential to cap-
ture a freeze frame of the precise state of pathway acti-
vation, in particular the phosphorylation status of key
elements [17]. Much emphasis is given to the retrieval
and processing needs of tissue, but almost always this
commences after the tissue is removed from the patient
and thus surgical ischaemic effects will already have
taken place. The resource that has gone into tissue
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banking in very many centres is vast [18], but the ben-
efits, although significant, have yet to appear in the
clinic and are rather more focused on key centres
where tissue collection is immediately linked to tissue
use for data generation. The evidence that tissue bank-
ing per se is beneficial, and a good return on invest-
ment, is a moot point. The real problem, especially in
large tumours, is that the blood supply to the tissue
may be cut off for some minutes before tissue is
retrieved, allowing significant transcriptional changes
and post-translational modification to occur. So the
question arises: how can one use human tissue effec-
tively? The answer depends on what is required. There
is no doubt that for discovery, and in the case of sys-
tems medicine, optimal tissue and data are required.
Tissue banking in such a manner may require large
expenditure and a huge logistical effort, but as long as
it deals with all the tissue, including the pre-analytical
challenges alluded to above, it can result in very high
quality data that can be reliably used by the primary
investigators but also made available for other groups.
For the implementation of systems medicine into rou-
tine practice the models and knowledge derived from
the gold card approach must be reduced to clinical
utility (Fig. 2) [19]. It is unlikely that a patient present-
ing in the middle of the night with an obstruction in
the bowel caused by a cancer will have access to all
the facilities necessary for discovery platforms; how-
ever, we still want to give that patient the maximum
amount of information for their future management.
This means that the data collected, even if severely
limited, must be fitted to a model and the predictive
information derived should be applicable to every
patient presenting in clinic. The addition of high
throughput technologies such as transcriptomics cer-
tainly produces a wealth of data but the sifting of
these data, to decide what is needed and what is not,
provides additional challenges. So, in many real life
settings a systems approach will deliberately limit the
amount of data collected or derived from the studied
tissue, because too much data introduces the likeli-
hood of error and artefact caused by uncontrollable
changes occurring in a sample attained within the clin-
ical setting. To deal with imperfection in clinical sam-
ples is thus first to acknowledge it and then to seek to
know the correct amount of information, providing
that the information obtained is robust and an ade-
quate surrogate, to describe the underlying signalling
pathway behaviour. That prompts the question, what
is the correct amount of information? This, however,
can only be determined empirically and will vary from
situation to situation.
Disease is heterogeneous
Histopathology has emphasized the heterogeneity of
disease processes, principally by describing differences
in morphological appearance. Whilst a primary and
metastatic tumour may appear very similar morpho-
logically the molecular phenotype may differ, whereas
there may also be marked variation in appearance
within a single primary tumour [20,21]. But pathology
does not necessarily reflect underlying genetic hetero-
geneity, and genetic heterogeneity may not be reflected
in differing morphology [22]. Furthermore, heterogene-
ity may exist at many different levels due to mutation
status, stem cell niche, hypoxic areas, chromatin struc-
ture or methylation, and the science of relating these
levels of data to the objectives of 4P medicine are lar-
gely unexplored. Some models have extrapolated from
a cell-based biochemical signalling pathway to a cancer
tissue without perhaps accounting in full for the het-
erotypic nature of cancer (composed of cancerous
and non-cancerous elements) and its heterogeneity
Fig. 2. Clinical impact on the stratification
of patients from quantified
immunofluorescence protein expression.
The left panel shows the Kaplan–Meier
survival curve for breast cancers treated
with herceptin segregated according to
PTEN expression. The right panel shows
quantitative, multichannel fluorescence
with DAPI stained nuclei in blue, tumour
cells in green and PTEN expression in red.
(Figure reproduced from [11].)
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(variation in genetic aberration across different parts
of the tumour). Histopathology has itself not ade-
quately resolved how heterogeneity affects outcome
(prognosis or prediction) despite years of empiricism,
in part due to problems of lack of standardization and
consistency. This is an exciting challenge for systems
medicine on a multiscale level. There are very practical
issues to consider. For example, if a mutation in
EGFR is crucial to determine whether a patient should
receive a drug to treat lung cancer [23] then one has to
question whether it is legitimate to assume that a tiny
biopsy, perhaps < 100 cells, is sufficient to categorize a
tumour as mutant or not. The imperfection of clinical
practice is that no more tissue is available and so a
huge assumption has to be made. The corollary of this
is that too large a sample of tumour may give evidence
of heterogeneity that we are uncertain how to use.
Interestingly pathology has already solved this prob-
lem empirically as its scoring systems for predictive bi-
omarkers usually combine an indication of both
intensity and variability of expression [6]. Whether this
empirical solution, which works for groups of patients,
can be reduced to work at a personalized level needs
to be investigated. This discussion is largely relevant to
cancer tissues but the same general principles apply to
any study relying on tissue, with organs such as brain
showing marked variation in structure, appearance
and function in health and disease. A further impor-
tant consideration is what part of a tumour is actually
important. In many studies, certainly in those requir-
ing transcript analysis from homogenized samples,
there is an assumption that the mass effect should
mean something. However, if < 1% of a tumour is
composed of the cells that actually generate the prog-
eny that cause growth, spread and ultimately death we
may be spending inordinate amounts of money to get
the right answer to the wrong question. Laser capture
microdissection of heterogeneous subpopulations
within the tissue section allows its purification and
quantification for predictive studies. Similarly whole
slide imaging coupled with automated image analysis
and spatial statistics delivers continuous immunohisto-
chemical and morphological data from heterogeneous
tissue and information on how it interacts with itself
and the host. These techniques may yield a higher
chance of success for systems medicine as heterogene-
ity will affect the entire model and its ability to predict
the long-term effectiveness of set treatments for overall
tumour reduction and long-term repression at the per-
sonal level. Systems medicine must go hand in hand
with a greater understanding of tumour biology in all
its variation and complexity to adopt a truly systems
approach.
Pathology is a two-dimensional
artefact
Histopathology for much of its existence as a disci-
pline has relied upon a two-dimensional artefact,
stained with antiquated histochemical techniques and
viewed by transmission light microscopy to deduce
behaviour, both past and future, in a dynamic three-
dimensional way. The addition of monoclonal antibod-
ies and latterly RNA and DNA extraction have
allowed in-depth analyses of some components, but
bizarrely histopathology for all of this still remains the
best working model available for many diseases. It is
apparent that the artefact of a tissue section is in fact
a distillation of a complex phenotype, a surrogate of
DNA, RNA, proteome, methylome, metabolome all
rolled into one without any clear guidebook of how to
balance different features. The application of quantita-
tive automated image analysis techniques, e.g. mor-
phometry and quantitative immunofluorescence,
encourages the pathologist to provide more dynamic
raw data to the modeller allowing greater awareness of
the spatial and presumably temporal variation that
occurs [8]. Automated image analysis of cellular phe-
notypes, or high content biology, has already been
adopted and implemented within pharmaceutical drug
discovery pipelines [24]. The application of digital and
quantitative techniques to pathology has long been
heralded but is slow to arrive in routine use [25]; how-
ever, we are now seeing the rapid emergence of the
new field of digital pathology. In part this may be due
to the problems discussed above where the object has
been to achieve perfection of data input rather than
utility of model output. A recent study implemented
unsupervised automated image analysis and discovered
that the stromal features, i.e. non-tumour cell charac-
teristics, of breast cancer showed a marked relation-
ship to prognosis [26]. Whilst there is a risk in these
studies of overfitting data to solutions, this shows an
exciting step forward in image analysis. Previous
studies going back decades have associated nuclear
size with outcome in diseases as disparate as bladder
and ovarian cancer [27,28]. Measuring nuclear DNA
ploidy using flow cytometry was a hugely popular pas-
time for a while but delivered almost nothing of gener-
alizable clinical value [29]. Pathologists of course had
got there first, with the ordinal scale of tumour grade
as an estimate of nuclear size and presumably aggres-
siveness! In many situations this is indeed the case, but
not always, perhaps pointing to differences in underly-
ing mechanisms. More recently digital image analysis
and parallel computing have allowed greater study
of quantitative characteristics of cancer [30]. Whilst
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unsupervised studies have their place there is also a
move to using image analysis to identify and measure
features of interest such as lymphovascular invasion,
tumour budding and nuclear grade in colon cancer
(Fig. 3). Whether these measured features mean any-
thing, in the sense that they contribute to refining the
personalized and predictive nature of the diagnosis,
remains to be seen but the advent of these approaches
is perfect for systems medicine as they encourage ques-
tions, experimentation and iteration of a model and
thus fulfil classical criteria for the application of sys-
tems approaches. Greater automation is unlikely to
replace pathology for some time if at all, but the
incorporation of fully quantifiable and continuous
data, not otherwise captured in an appropriate model,
may further harness the value of tissue morphology
which despite all the advances in molecular biology
still remains the best single investigative tool we have.
All measurements and assessments made on tissue are
based on an artefact, a surrogate of what is really
A B C
D
Fig. 3. Automated quantification of prognostic histopathological features in a colorectal tissue microarray (TMA) core through digital
pathology. The TMA was stained by immunofluorescence using antibodies against pan-cytokeratin (epithelium, green) and D240 (lymphatic
endothelium, red) and counterstained with DAPI (nucleus, blue). (A) The image was captured and digitized prior to importing into Definiens
Developer XDTM software. (B) Utilizing the DAPI image layer all nuclei within the TMA were segmented and quantified for intensity and
morphometric parameters. (C) Combining the three image layer wavelengths the image was first segmented into stroma, tumour and
necrosis/lumen. Second, tumour buds and lymphatic vessels were quantified through the pan-cytokeratin (marker 1) and D240 (marker 2)
image layers respectively. A combination of epithelium, as tumour and tumour bud, and D240 colocalization (markers 1 and 2) along with
quantification and classification of bordering epithelial and D240 markers was employed to quantify LVI (lymphatic vessel invasion).
Intensity, spatial and morphometric single object parameters may be quantified from within the tumour and its microenvironment. (D) To
quantify tumour grade and the nuclei within the invasive microenvironment while retaining their heterogeneity, single object nuclei intensity,
texture and morphometric parameters were quantified and classified within separate subpopulations of ‘tumour’, ‘stroma’ and ‘tumour bud’.
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happening, fixed at one point in time. Using that
knowledge opens new conceptual avenues.
Pathology is imaginary!
But sometimes dreams come true. Histopathology is
essentially visual, confirming that meaning inferred
may be more rich and complex than simply multiple
measured data sets. Thus, the future of systems pathol-
ogy and medicine may be to visualize processes, build-
ing in methods that allow filling-in where data are
incomplete and prompting focus of research efforts
where gaps appear in the picture. Systems approaches
are showing us how we can use complex large data
sets to build useful models to better understand disease
and how to treat it. Clinical implementation will
require a sifting of those data to ensure that (a) mod-
els work and can be iteratively improved and refined,
(b) data that are quality assured and sufficient can be
gathered in real clinical settings and (c) we keep an
awareness that we have an empirical tool in pathology
that works remarkably well and that we should seek
to add value to it rather than simply to substitute an
alternative.
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